You may know the name Moderna (NASDAQ:MRNA) very well thanks to the company's blockbuster coronavirus vaccine. That was the biotech's first commercialized product, highlighting its expertise in messenger RNA technology. This involves teaching the body to make proteins that will prevent or fight a certain disease. Moderna launched its coronavirus vaccine in early pandemic days and saw revenue and stock performance skyrocket. As demand declined later in the crisis, the company's earnings and stock price also suffered. But Moderna took steps to turn things around, including cost cuts, a focus on oncology and rare-disease candidates, and the release of new products. All of this boosted investor optimism, putting the stock on track for triple-digit gains this year. That's fantastic, but news this week prompted the stock to drop 17% in one trading session. After stumbling, is Moderna stock a buy on the dip? Let's find out.
CryptoAlerta — análise de criptomoedas e mercado em tempo real